Janus Henderson Group PLC Sells 16,861 Shares of Laboratory Co. of America Holdings (NYSE:LH)

Janus Henderson Group PLC trimmed its position in Laboratory Co. of America Holdings (NYSE:LH - Free Report) by 9.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 166,211 shares of the medical research company's stock after selling 16,861 shares during the quarter. Janus Henderson Group PLC owned approximately 0.20% of Laboratory Co. of America worth $38,116,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of LH. Graney & King LLC acquired a new stake in Laboratory Co. of America in the 4th quarter worth approximately $26,000. Geneos Wealth Management Inc. grew its holdings in Laboratory Co. of America by 309.8% during the 4th quarter. Geneos Wealth Management Inc. now owns 168 shares of the medical research company's stock worth $39,000 after acquiring an additional 127 shares during the period. Human Investing LLC acquired a new stake in Laboratory Co. of America during the 4th quarter worth $39,000. Heck Capital Advisors LLC acquired a new stake in Laboratory Co. of America in the 4th quarter valued at approximately $44,000. Finally, SBI Securities Co. Ltd. acquired a new position in Laboratory Co. of America during the fourth quarter worth $52,000. Institutional investors and hedge funds own 95.94% of the company's stock.

Insider Transactions at Laboratory Co. of America

In other Laboratory Co. of America news, Director Kerrii B. Anderson sold 500 shares of Laboratory Co. of America stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $255.63, for a total value of $127,815.00. Following the transaction, the director now directly owns 13,166 shares in the company, valued at approximately $3,365,624.58. The trade was a 3.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CMO Amy B. Summy sold 226 shares of the stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $250.40, for a total transaction of $56,590.40. Following the sale, the chief marketing officer now owns 4,544 shares of the company's stock, valued at $1,137,817.60. This trade represents a 4.74% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 16,971 shares of company stock worth $4,193,073. 0.84% of the stock is currently owned by insiders.

Laboratory Co. of America Stock Up 0.5%

Shares of NYSE LH traded up $1.18 during midday trading on Tuesday, hitting $250.98. The company's stock had a trading volume of 66,028 shares, compared to its average volume of 640,161. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.44 and a quick ratio of 1.30. Laboratory Co. of America Holdings has a 1 year low of $191.97 and a 1 year high of $258.59. The firm has a market capitalization of $21.01 billion, a price-to-earnings ratio of 28.48, a price-to-earnings-growth ratio of 1.71 and a beta of 0.82. The business's fifty day simple moving average is $233.83 and its two-hundred day simple moving average is $237.86.

Laboratory Co. of America (NYSE:LH - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The medical research company reported $3.84 earnings per share for the quarter, topping the consensus estimate of $3.73 by $0.11. The company had revenue of $3.35 billion for the quarter, compared to the consensus estimate of $3.41 billion. Laboratory Co. of America had a return on equity of 15.29% and a net margin of 5.73%. Laboratory Co. of America's revenue was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.68 EPS. On average, equities analysts predict that Laboratory Co. of America Holdings will post 16.01 EPS for the current year.

Laboratory Co. of America Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 11th. Shareholders of record on Thursday, May 29th will be issued a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a yield of 1.15%. Laboratory Co. of America's payout ratio is currently 33.29%.

Wall Street Analyst Weigh In

LH has been the topic of several recent analyst reports. Barclays lifted their price target on Laboratory Co. of America from $240.00 to $250.00 and gave the company an "equal weight" rating in a research note on Wednesday, April 30th. Citigroup raised shares of Laboratory Co. of America from a "neutral" rating to a "buy" rating and lifted their price objective for the stock from $250.00 to $300.00 in a report on Tuesday, March 4th. UBS Group dropped their target price on Laboratory Co. of America from $293.00 to $286.00 and set a "buy" rating on the stock in a research report on Tuesday, January 28th. Truist Financial upped their price objective on Laboratory Co. of America from $274.00 to $290.00 and gave the stock a "buy" rating in a report on Monday, May 12th. Finally, Piper Sandler restated a "neutral" rating and issued a $280.00 target price (up previously from $260.00) on shares of Laboratory Co. of America in a report on Tuesday, May 6th. Four research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $270.62.

About Laboratory Co. of America

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.